Oslo, Norway, 13 January 2025: Reference is made to the stock exchange
announcement made by Photocure ASA ("Photocure" or the "Company") on 19 December
2024 of the launch of Photocure's program to repurchase up to 300,000 of its own
shares for a total maximum amount of NOK 30 million during the period from 19
December 2024, until no later than 31 March 2025, pursuant to an agreement with
DNB Markets.

For the period from and including 19 December 2024, through 10 January 2025, the
Company purchased a total of 258,670 shares at an average price of NOK 60.97 per
share, all purchased as ordinary market purchases on Euronext Oslo BÃ¸rs. Please
find below the transaction overview:

    Date       Aggregated daily   Weighted average       Total daily
               volume (#shares)  share price per day  transaction value
                                        (NOK)               (NOK)
 06.01.2025         20 758              59.13             1,227,414
 07.01.2025         20,114              59.01             1,186,850
 08.01.2025         22,725              58.93             1,339,138
 09.01.2025         21,658              58.92             1,276,188
 10.01.2025         22,613              58.72             1,327,907
 Previously        150,802              62.43             9,414,253
  disclosed
  buybacks
  under the
   program
(accumulated)
 Accumulated       258,670              60.97            15,771,753
  under the
   program

The issuer's holding of own shares:
Following the completion of the above transactions, Photocure owns a total of
273,792 of own shares (including 15,122 shares owned prior to the launch of the
buyback program), corresponding to 1.01% of Photocure's share capital.

Appendix:
An overview of all transactions made under the buyback program that have been
carried out during the above-mentioned time period is attached to this report
and available at www.newsweb.no.

For further information, please contact:

Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com and www.cysview.com. All trademarks mentioned in this release
are protected by law and are registered trademarks of Photocure ASA.

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This information is made public by Photocure ASA pursuant to the EU Market Abuse
Regulation and subject to the disclosure requirements pursuant to Section 5-12
of the Norwegian Securities Trading Act.


